Ocugen Raises $130 Million Through Convertible Notes Offering

Ocugen ( (OCGN) ) has shared an update.

On May 7, 2026, Ocugen closed a private offering of $115 million in 6.75% Convertible Senior Notes due 2034 and, on May 14, 2026, issued an additional $15 million after the full exercise of the over-allotment option, bringing the total to $130 million. The notes, sold to qualified institutional buyers at 90% of principal, generated approximately $112.6 million in net proceeds, of which about $32.7 million was used to fully repay Ocugen’s Avenue Capital loan, with the remaining funds earmarked for general corporate purposes and extending the company’s cash runway into 2028 to support three late-stage programs and planned regulatory filings.

The notes may be settled in cash, stock or a combination upon conversion, although conversions will be settled solely in cash until a reserved share condition is met, and up to 8,108,108 shares could ultimately be issued, highlighting potential dilution for existing shareholders. By refinancing debt and bolstering liquidity through this Rule 144A convertible issuance, Ocugen strengthens its balance sheet and gains financial flexibility to advance its late-stage ophthalmic pipeline, a development closely watched by institutional investors and stakeholders in the biotech and gene therapy sectors.

The most recent analyst rating on (OCGN) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.

Spark’s Take on OCGN Stock

According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.

Overall score is constrained primarily by weak financial performance (persistent losses, ongoing cash burn, and a stressed balance sheet) and bearish technicals (below major moving averages with negative MACD). These are partially offset by a comparatively strong earnings-call read-through driven by concrete regulatory timelines and positive clinical progress, though financing and execution risks remain key.

To see Spark’s full report on OCGN stock, click here.

More about Ocugen

Ocugen, Inc., based in Malvern, Pa., is a biotechnology company focused on gene therapies for blindness diseases. Its modifier gene therapy platform targets inherited retinal disorders and other blindness conditions such as retinitis pigmentosa, Stargardt disease and geographic atrophy, aiming to address large patient populations through a gene-agnostic approach.

Average Trading Volume: 9,025,329

Technical Sentiment Signal: Sell

Current Market Cap: $497.6M

For a thorough assessment of OCGN stock, go to TipRanks’ Stock Analysis page.